新的后房型散光型有晶状体眼人工晶状体植入治疗中高度近视合并散光的 1 年随访结果。

One-year follow-up of a new posterior chamber toric phakic intraocular lens implantation for moderate-to-high myopic astigmatism.

机构信息

Department of Ophthalmology, Idil State Hospital, 73300, Şırnak, Turkey.

Ataköy Dünya Göz Hospital, Istanbul, Turkey.

出版信息

Int Ophthalmol. 2021 Sep;41(9):2941-2949. doi: 10.1007/s10792-021-01853-7. Epub 2021 Apr 20.

DOI:10.1007/s10792-021-01853-7

PMID:33880683

Abstract

PURPOSE

To investigate refractive and visual outcomes as well as rotational stability following implantation of Eyecryl phakic toric intraocular lens (pIOL) for moderate-to-high myopic astigmatism.

METHODS

The efficacy, safety, predictability, stability, and adverse events of Eyecryl toric pIOL were evaluated in patients with spherical refraction from - 4.50 to - 18.50 diopters (D) and cylindrical refraction from - 0.50 to - 5.50 D.

RESULTS

This study included 60 eyes of 31 patients. The mean manifest refraction spherical equivalent (MRSE) dropped from - 10.45 ± 2.74 D preoperatively to - 0.34 ± 0.51 D and - 0.40 ± 0.56 D at 6 and 12 months postoperatively, respectively. There was an 81% decrease in astigmatism after surgery. The safety and efficacy of indices were 1.36 ± 0.43 and 1.20 ± 0 .32. At the final follow-up, the rate of eyes within ± 1.00 D and ± 0.50 D of the desired MRSE were 85% and 68.33%, respectively. Vision-threatening complications were not observed during the follow-up.

CONCLUSIONS

The implantation of pIOL was effective, safe, and predictable in patients with moderate-to-high myopic astigmatism during 1-year follow-up.

摘要

目的

研究中度至高度近视散光患者植入 Eyecryl 有晶状体眼屈光性环形多焦点人工晶状体（pIOL）后的屈光和视觉结果以及旋转稳定性。

方法

评估 Eyecryl 环曲面 pIOL 在球镜屈光度为-4.50 至-18.50 屈光度（D）和柱镜屈光度为-0.50 至-5.50 D 的患者中的疗效、安全性、可预测性、稳定性和不良事件。

结果

这项研究共纳入 31 例 60 只眼。平均术前显微微镜下等效球镜（MRSE）从-10.45±2.74 D 降低至术后 6 个月的-0.34±0.51 D 和 12 个月的-0.40±0.56 D。术后散光降低了 81%。术后 6 个月和 12 个月，安全性和有效性指数分别为 1.36±0.43 和 1.20±0.32。末次随访时，85%的眼在±1.00 D 和±0.50 D 范围内达到期望的 MRSE，68.33%的眼达到期望的 MRSE。在随访期间未观察到视力威胁性并发症。